GlassScriptPhysician profile
Ernst M Klaus
NPI 1639887771
$8,607.23
in general payments reported to CMS, 2019-2025
32 companies · $2,006 in 2025
The $2,006 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,944 · 2024: $3,657 · 2025: $2,006.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,506 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,505.96 |
| Education | $101.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,297.40 | 2023-2025 | |
| Amgen INC. | $1,272.80 | 2023-2025 | Enbrel, Evenity, Tavneos |
| Ucb, INC. | $888.66 | 2023-2025 | Cimzia, Bimzelx |
| Mallinckrodt Hospital Products INC. | $561.39 | 2023-2025 | Acthar |
| Pfizer INC. | $549.58 | 2023-2025 | |
| Glaxosmithkline, LLC. | $537.24 | 2023-2025 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $469.32 | 2023-2025 | Orencia |
| Janssen Biotech, INC. | $452.55 | 2023-2025 | Tremfya, Simponi Aria, Simponi |
| Lilly USA, LLC | $450.01 | 2023-2025 | Taltz, Zepbound, Olumiant |
| Fresenius Kabi USA, LLC | $363.57 | 2023-2025 | Idacio, Tyenne |
| Boehringer Ingelheim Pharmaceuticals, INC. | $339.88 | 2023-2025 | Ofev |
| Radius Health, INC. | $279.13 | 2023-2025 | Tymlos |
| Astrazeneca Pharmaceuticals LP | $276.08 | 2023-2025 | Saphnelo, Flumist Quadrivalent |
| Sobi, INC | $161.76 | 2023-2025 | |
| Aurinia Pharma U.S., INC. | $122.89 | 2024-2025 | Lupkynis |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $73.92 | 2023-2024 | Hyrimoz |
| Ibsa Pharma INC. | $72.51 | 2024-2025 | Licart, Tirosint, Flector |
| Horizon Therapeutics Plc | $62.78 | 2023 | Krystexxa |
| Mannkind Corporation | $36.77 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.61 | 2024-2025 | |
| Organon LLC | $34.74 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $34.59 | 2023-2024 | Truxima |
| Genzyme Corporation | $32.36 | 2025 | |
| Ani Pharmaceuticals, INC. | $30.87 | 2025 | Purified Cortrophin Gel |
| Kyowa Kirin, INC. | $28.90 | 2025 | |
| Alexion Pharmaceuticals, INC. | $27.72 | 2024 | Strensiq |
| Novo Nordisk INC | $27.19 | 2024 | Wegovy |
| Tandem Diabetes Care, INC. | $22.36 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Scilex Pharmaceuticals INC. | $18.42 | 2025 | |
| Recordati_rare_diseases_inc. | $16.88 | 2025 | Isturisa |
| Exact Sciences Corporation | $15.02 | 2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $13.33 | 2024 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ernst Klaus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.